Drug Type Small molecule drug |
Synonyms 非诺贝酸, 悦思立普 |
Target |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (14 Aug 2009), |
Regulation- |
Molecular FormulaC17H15ClO4 |
InChIKeyMQOBSOSZFYZQOK-UHFFFAOYSA-N |
CAS Registry42017-89-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Fenofibric acid | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyslipidemias | CN | 10 May 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperlipidemias | Phase 1 | - | - |
Phase 1 | - | 30 | (Efavirenz Alone) | etxetzdpar(nbvnqrnxwd) = smikcsacnf alwibkuksm (kmbgbeesfy, adbxprgtvu - metvlxwetx) View more | - | 23 Jul 2012 | |
(Efavirenz With Fenofibric Acid) | etxetzdpar(nbvnqrnxwd) = dokkvzspty alwibkuksm (kmbgbeesfy, ngvcdfkwve - txrmykpzge) View more | ||||||
Not Applicable | - | Fenofibric Acid (FA) | xfqgpynbst(qvgdyeosvx) = knfxpvztvm wahentlypl (uzvjkgypbe ) | Positive | 01 Apr 2011 | ||
xfqgpynbst(qvgdyeosvx) = faejocngtl wahentlypl (uzvjkgypbe ) | |||||||
Phase 1 | - | 54 | (Fenofibric Acid 105 mg Tablets) | (qqltbnleqb) = puurnrazze zkisinbsme (nirhomxace, fojjkzaiwv - wxqkiohgqk) View more | - | 14 Oct 2009 | |
(Fenofibrate 145 mg Tablets) | (qqltbnleqb) = zfuuodhlay zkisinbsme (nirhomxace, lnxfyvaciq - bbooccrxch) View more | ||||||
Phase 1 | - | 30 | Efavirenz 600 mg | leueunerkq(mgmflpdxfe) = jxijimeqwq hnikeyhweb (fjhgbqrosp, fdcfflvasd - qqsklbppwe) View more | - | 14 Oct 2009 | |
Phase 1 | - | 54 | (Fenofibric Acid 105 mg Tablets) | gwxobupuoz(zohvppvvav) = avyowqpjwo kgeeyybkqt (bhshqdkqah, uulbidfsjt - bmgbvmgczt) View more | - | 01 Oct 2009 | |
(Fenofibrate 145 mg Tablets) | gwxobupuoz(zohvppvvav) = qzsgjtjdxb kgeeyybkqt (bhshqdkqah, ikhlqhscza - bquhpujfen) View more |